|
|
 |
|
Viewing report
|
|
|
|
Toward a Biogenerics Market: The Regulatory Conundrum
Decision Resources, Inc., Dec 2007, Pages: 31
The sales that biologic agents command and the costs that they impose for payers combine to generate intense interest in the development of generic biologic agents, or biogenerics. However, the biogenerics market has been very slow to establish itself. The key reason is the lack of a defined regulatory framework and uncertainty—on the part of manufacturers and regulators alike—regarding what biogenerics will look like and how they will reach the market.
Get the Answers You Need to Shape Your Strategy
In the spring of 2006, two companies made history by producing the fi rst two approved biogenerics in the European Union.
Which two companies were they, and what products were approved?
What steps has the European Medicines Agency (EMEA) taken to clarify the path to approval?
The biologics that bring in the most sales will be the natural focus of biogeneric development.
Which branded biologics are the most popular targets?
In late September 2006, Representative Henry Waxman introduced the Access to Life-Saving Medicine Act, which would amend section 351 of the Public Health Service Act.
How could this bill foster the development of biogeneric products in the United States?
What other actions are interested parties taking?
Several generic drug manufacturers have entered or are hoping to enter the biogenerics market
Which companies are they and which biological products are they targeting?
What businessmodels are they using?
Scope
The biologics market: origins and progress.
The regulatory pathway for biologics: United States and Europe.
The biogenerics market: origins and progress.
Current and potential regulatory pathways for biogenerics: United States and Europe.
Select company profi les: biopharmaceutical companies and biogenerics companies.
Customers who bought this item also bought
A Guide to Biosimilars, Biogenerics and Follow-On Biologics
Biosimilars, Biogenerics and Follow-On Biologics
Business Strategies for Different Types of Biogenerics
Biogenerics: Challenges and Promise
The Anemia Market: Biogenerics and Second-Generation Products Drive Change
Biogenerics 2005: A New Level Of Complexity
The Biogenerics Market Outlook: An Analysis of Market Dynamics, Growth Drivers and Leading Players
Strategic Analysis of the World Biogenerics Market
World Generics and Biogenerics Markets
Competitor Analysis: Biogenerics & Therapeutic Proteins
Biogenerics - Global Strategic Business Report
Biogenerics: Drivers and Resistors of Market Development
|
|
|
|
